We are live on ! Find out more
ARVN icon

Arvinas

82 hedge funds and large institutions have $348M invested in Arvinas in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

123% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 13

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

41% more capital inflows, than outflows

Capital inflows: $54.6M | Capital outflows: $38.8M

22% more funds holding

Funds holding: 67 → 82 (+15)

0.2% less ownership

Funds ownership: 48.03% → 47.82% (-0.2%)

Holders
82
Holders Change
+15
Holders Change %
+22.39%
% of All Funds
1.79%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
21
Increased
29
Reduced
13
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ARVN Hedge Fund Activity: Q3 2019 in Review

82 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Arvinas (ARVN) for Q3 2019, worth a combined $348M — up 1.8% from $341M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ARVN positions and 7 closed out — a net gain of 14 holders — while 29 added to existing stakes and 13 trimmed.

The largest buyer was Bellevue Group, opening a new position worth an estimated $19.8M. The largest seller was OrbiMed, cutting an estimated $14.3M.

  • 82 institutional investors held Arvinas (ARVN) as of Q3 2019, up from 67 in Q2 2019.
  • Funds reported $348M of Arvinas stock for Q3 2019, up 1.8% quarter-over-quarter.
  • 21 funds opened new Arvinas positions in Q3 2019 and 7 closed out, a net change of +14 holders.
  • The largest Arvinas buyer in Q3 2019 was Bellevue Group, an estimated $19.8M added.
  • The largest Arvinas seller in Q3 2019 was OrbiMed, an estimated $14.3M sold.

Based on aggregated 13F filings for Q3 2019.